Triple meeting 2024 – Tyra’s targeted FGFR3 push
The company reckons it’s got what it takes to hit the right member of the FGFR family.
Triple meeting 2024 – Aktis radiotherapy heads for the clinic
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.
European radiopharmaceuticals head for the clinic
First-in-human study starts include radioligands from Akiram and Philogen.
Not so B-Fast for Roche
The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.
